WS #37

The key market-moving signal in this data window is the release of US CPI data for February, which came in exactly in line with expectations across all metrics: YoY CPI at 2.4% (vs 2.4% est), MoM CPI at 0.3% (vs 0.3% est), and Core YoY at 2.5% (vs 2.5% est). This confirmation of stable inflation without surprises reduces immediate uncertainty about Federal Reserve policy, likely supporting equity markets in the next few hours as it eliminates a potential negative catalyst. The data corroborates across multiple pro-wire items, indicating high reliability. Secondary signals include corporate developments with specific market implications. Tredegar Corporation reported strong Q4 results with adjusted EPS of $0.32 (up from $0.06 YoY) and sales of $154.505M (up from $122.462M YoY), which could positively impact its stock (TG) given the significant earnings beat. IceCure Medical received FDA approval for study design for its ChoICE trial post-market study, with participant enrollment expected in H2 2026, potentially boosting its shares (ICCM) as regulatory milestones often drive biotech valuations. Energy market commentary continues with U.S. Interior Secretary Burgum stating on Fox News that Texas refineries, Venezuela, and oil reserves will help bring down gas prices, suggesting proactive government measures to address energy costs. This follows earlier TotalEnergies project news, indicating ongoing supply-side developments that could stabilize energy markets. The Fitell rebranding to GMEX Robotics (effective March 12) represents continued capital allocation toward AI/robotics, though with less immediate impact than the macroeconomic data. Other items, including routine SEC filings, weather alerts, and non-market news (e.g., UK banknote changes, Iranian asylum case), constitute noise with minimal actionable implications for US financial markets in the next 1-8 hours.